|
Játtað í: 2019 Granskingarøki: Heilsa - Sjúkrakassagrunnurin Verkætlanarslag: R&D Verkætlanarheiti: Microbiom and Parkinson’s disease Játtanarnummar: 3026 Verkætlanarleiðari: Maria Skaalum Petersen Stovnur/virki: Deildin fyri Arbeiðs og Almannaheilsu Aðrir luttakarar: Prof. Beate Ritz, Sára Bech, Súsanna Crooks, Pál Weihe, Jan Aasley og Matthew Farrer. Verkætlanarskeið: 01.01.2021-31.12.2024 Samlaður kostnaður: kr. 1.576.942 Stuðul úr Granskingargrunninum: kr. 851.734 Verkætlanarlýsing: The human microbiome has a major role in uptake and handling of nutrients, medications, and toxins; and is of great immune system relevance. Evidence is mounting that it can affect aspects of neurologic function, brain activity, and behavior via the ‘gut-brain-axis’ and that it plays a role in Parkinson’s disease (PD). PD is a complex and progressive neurodegenerative disease with non-motor symptoms that include gastro-intestinal (GI) features such as constipation and gastro-paresis. Pathologic hallmarks of PD, namely Lewy bodies and α-synuclein aggregates, and inflammation have been found in the gut of PD patients. The role of the gut microbiome in PD is underexplored and no Nordic study has to our knowledge addressed the microbiome influences on PD yet. We will capitalize on the Faroese Parkinson's cohort resources to explore the hypotheses that an altered gut microbiome contributes to the onset of neurodegeneration in PD. We propose to analyze the bacterial gut flora of 50 Faroese PD patients and 100 matched controls (50 household & 50 community controls) using 16S ribosomal RNA to assess microbiome differences between patients vs. controls. Importantly, we will also newly enroll 20 new-onset, medication naïve PD patients and another 40 (20 household and 20 community) controls and collect data on exposures, gut motility indicators in addition to fecal and blood samples. We will follow these drug-naïve PD patients and collect a second stool (and blood) sample one year after they started their PD medications and assess compositional biota differences over time. Our research may contribute to the discovery of potentially novel etiologies and treatment options in PD and neurodegeneration in general. Our research may contribute to the discovery of potentially novel etiologies and treatment options in PD and neurodegeneration in general. Støða: Virkin Avrik: See PURE << Back |
| Administration English |